Drawing for ONCOREVEAL

USPTO serial 90532971

ONCOREVEAL

Reviewed by CopyMark Law Group

Reg. 7634070Status 700Registered
Filing date
Status date
Registration date
Dec 31, 2024
Examiner
CLYBURN, CARLA DIONNE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ONCOREVEAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Andrew T. Pettit

Andrew T. Pettit PERKINS COIE LLPP.O. Box 2608Seattle, WA 98111United States

Goods and services

ClassDescriptionStatusFirst use
035Data processing services for medical, clinical, and scientific purposesACTIVEMar 16, 2022
042Software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for collecting, managing, and analyzing data in the fields of scientific research, clinical research, scientific diagnostics, and medical diagnostics; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for analyzing biological samples; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, scientific diagnostics research, and medical diagnostics; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; software as a service (SaaS), namely, hosting non-downloadable computer software for health and wellness assessment, namely, for genomic analysis; software as a service (SaaS), namely, hosting non-downloadable computer software for genetic and bioinformatics analysis; bioinformatics services, namely, product research and development in the field of bioinformatics; data processing services for medical, clinical, and scientific purposes; developing diagnostic testing models for others for medical, clinical, and scientific purposes; Genetic testing for scientific research purposes; Scientific consulting relating to scientific researchACTIVEMar 16, 2022
044Providing biological sample testing services for others in the field of medical diagnostics; providing biological sample testing services for others for medical purposes, namely, for the diagnosis and treatment of cancer; providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the field of medical diagnostics; genetic testing for medical and clinical medical purposes; medical testing for diagnostic and treatment purposes; consulting services for medical and clinical medical purposes, health and wellness assessment services; providing health and wellness informationACTIVEMar 16, 2022

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 31, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Dec 31, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 25, 2024SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Oct 25, 2024CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Sep 9, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 9, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 6, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 4, 2024XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Jun 4, 2024XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Mar 8, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 8, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 8, 2024CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 6, 2024DPCCDIVISIONAL PROCESSING COMPLETE—
Feb 6, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 31, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 31, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 31, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 30, 2024DRRRDIVISIONAL REQUEST RECEIVED—
Jan 30, 2024ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Oct 30, 2023XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Oct 30, 2023XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Jul 31, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 31, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 31, 2023CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 7, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 7, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 7, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 7, 2023ALIEASSIGNED TO LIE—
Mar 8, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 8, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 8, 2023EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Mar 8, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 8, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 8, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 8, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 8, 2022CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 11, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 10, 2022SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Aug 10, 2022EX1GSOU EXTENSION 1 GRANTED—
Aug 10, 2022AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 1, 2022IUAFUSE AMENDMENT FILED—
Aug 1, 2022EXT1SOU EXTENSION 1 FILED—
Aug 1, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 1, 2022EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Feb 1, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 7, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 7, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 17, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 1, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 1, 2021XAECEXAMINER'S AMENDMENT ENTERED—
Nov 1, 2021GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 1, 2021GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 1, 2021CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 29, 2021ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Oct 19, 2021PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Oct 7, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 1, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 30, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 30, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 21, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 21, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 21, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 11, 2021DOCKASSIGNED TO EXAMINER—
May 21, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 23, 2021TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Feb 23, 2021PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Feb 20, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance